Last update Aug. 31, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
R05CA03 is Guaifenesin in ATC Code/s.Is written in other languages:
R05CA03 is also known as
R05CA03 belongs to this group or family:
Main tradenames from several countries containing R05CA03 in its composition:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is used as an expectorant, alone or in association with other products. Proofs on its effectiveness are sparse (Smith 2014, Reis 2010, Bolser 2006). In some instances, preparations of Guaifenesin may contain alcohol as excipient with a concentration as high as 5%. Oral administration every 4 to 6 hours.
At latest update, relevant published data on excretion into breast milk were not found.
Until more information on this medication is available, other option known to be safer would be recommended, mostly in the post-natal period or in cases of prematurity.
If used while breastfeeding, a moderate use with the lowest dose as possible and avoiding those preparations with alcoholic excipient, should be preferred.
Because effectiveness is poor and likelihood of side effects does exist, especially in multi-association, the US Agency for Drug Administration (FDA) is currently doing efforts for discontinuation of this and others at-the-counter products, that are formulated for cough relief: Guaifenesin, Dextromethorphan, Phenylephrine, Pseudoephedrine, Brompheniramine, etc. (FDA 2015)